ACAD · Acadia Pharmaceuticals Inc
United States · RS rating 35 · As of 2026-11-03
| Price | 20.57 USD |
|---|---|
| 1-day change | +0.5% |
| RS rating (overall / 1M / 3M / 12M) | 35 / 64 / 22 / 44 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 37 / 10 / 55 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +280.9% |
| Sales growth Q/Q | +1.9% |
| Distance from 52-week high | +32.7% |
| Market cap (USD) | $3.8B |